

CLAIMS

1. A Lymphocyte Activation Gene-3 (LAG-3) binding agent comprising:
an immunoglobulin light chain variable (V_L) region comprising a light chain CDR1, a light chain CDR2, and a light chain CDR3 of SEQ ID NO:88; and
an immunoglobulin heavy chain variable (V_H) region comprising a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of SEQ ID NO:182.
2. A Lymphocyte Activation Gene-3 (LAG-3) binding agent comprising:
an immunoglobulin light chain variable (V_L) region comprising SEQ ID NO:88; and
an immunoglobulin heavy chain variable (V_H) region comprising SEQ ID NO:182.
3. The LAG-3 binding agent of claim 1, wherein the LAG-3 binding agent is an antibody.
4. The LAG-3 binding agent of claim 1, wherein the LAG-3 binding agent is an antigen-binding antibody fragment.
5. The LAG-3 binding agent of claim 1, wherein the LAG-3 binding agent is an IgG4 antibody.
6. The LAG-3 binding agent of claim 2, wherein the LAG-3 binding agent is an antibody.
7. The LAG-3 binding agent of claim 2, wherein the LAG-3 binding agent is an antigen-binding antibody fragment.
8. The LAG-3 binding agent of claim 2, wherein the LAG-3 binding agent is an IgG4 antibody.
9. A pharmaceutical composition comprising the LAG-3 binding agent of claim 1 and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising the LAG-3 binding agent of claim 2 and a pharmaceutically acceptable carrier.